|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins.
|
19801490 |
2009 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
|
15994142 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
|
18086299 |
2007 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.
|
12839951 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
|
16091755 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.
|
25221644 |
2014 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
|
11583189 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation.
|
19617202 |
2011 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
|
12655533 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
|
11248153 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
|
18768436 |
2008 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
|
26124351 |
2015 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
|
19896266 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
|
16495393 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
Gene amplification and expression of the neu (c-erbB-2) sequence in human mammary carcinoma.
|
3412743 |
1988 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
|
17614302 |
2007 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides.
|
11222871 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
We conclude that P-IHC offers a favorable alternative to Southern analysis in the assessment of c-erbB-2 gene copy number of this oncoprotein in human mammary carcinoma.
|
7905629 |
1993 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
Amplification of HER-2 oncogene was analysed in DNAs obtained from 291 primary human mammary carcinomas.
|
2915900 |
1989 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
|
20332317 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
|
16234514 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
11970740 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.
|
16446318 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
|
19436038 |
2009 |